Brokerages expect Krystal Biotech Inc (NASDAQ:KRYS) to announce earnings of ($0.22) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Krystal Biotech’s earnings, with estimates ranging from ($0.24) to ($0.20). The business is expected to report its next quarterly earnings results on Monday, March 11th.

On average, analysts expect that Krystal Biotech will report full year earnings of ($0.95) per share for the current financial year, with EPS estimates ranging from ($1.13) to ($0.88). For the next fiscal year, analysts expect that the business will post earnings of ($1.31) per share, with EPS estimates ranging from ($1.54) to ($0.96). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Krystal Biotech.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 5th. The company reported ($0.26) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.26).

A number of equities analysts recently weighed in on KRYS shares. Zacks Investment Research upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Saturday, August 11th. Cantor Fitzgerald started coverage on shares of Krystal Biotech in a research report on Monday, September 10th. They set an “overweight” rating and a $28.00 target price for the company. ValuEngine upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Friday, September 21st. HC Wainwright started coverage on shares of Krystal Biotech in a research report on Monday, September 24th. They set a “buy” rating and a $32.00 target price for the company. Finally, William Blair restated a “buy” rating on shares of Krystal Biotech in a research report on Monday, November 5th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $32.60.

In other Krystal Biotech news, insider Krish S. Krishnan acquired 25,000 shares of the stock in a transaction on Thursday, October 18th. The stock was acquired at an average price of $20.00 per share, for a total transaction of $500,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 45.80% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC lifted its position in Krystal Biotech by 552.2% during the second quarter. Acadian Asset Management LLC now owns 12,202 shares of the company’s stock valued at $182,000 after purchasing an additional 10,331 shares during the last quarter. BlackRock Inc. lifted its position in Krystal Biotech by 75.4% during the second quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock valued at $194,000 after purchasing an additional 5,607 shares during the last quarter. P.A.W. Capital Corp bought a new position in Krystal Biotech during the third quarter valued at $527,000. JPMorgan Chase & Co. lifted its position in Krystal Biotech by 69.0% during the third quarter. JPMorgan Chase & Co. now owns 36,133 shares of the company’s stock valued at $635,000 after purchasing an additional 14,755 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in Krystal Biotech during the third quarter valued at $891,000. Institutional investors and hedge funds own 18.83% of the company’s stock.

Shares of NASDAQ:KRYS traded up $0.02 during midday trading on Friday, reaching $23.49. 52,664 shares of the company were exchanged, compared to its average volume of 51,470. Krystal Biotech has a one year low of $8.03 and a one year high of $28.75. The firm has a market cap of $338.65 million, a price-to-earnings ratio of -15.87 and a beta of -0.66.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.

See Also: Retained Earnings

Get a free copy of the Zacks research report on Krystal Biotech (KRYS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.